We are live on
!
Find out more
TEC
Tiger Eye Capital Portfolio holdings
AUM
$113M
1-Year Est. Return
11.44%
This Fund
S&P 500
This Quarter
Est. Return
+9.47%
1 Year Est. Return
-11.44%
3 Year Est. Return
+116.39%
5 Year Est. Return
+328.27%
10 Year Est. Return
–
AUM
$480M
AUM Growth
+$68.6M
(+17%)
Cap. Flow
+$33.5M
Cap. Flow
% of AUM
6.98%
Top 10 Holdings %
Top 10 Hldgs %
68.76%
Holding
52
New
8
Increased
12
Reduced
11
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Upland Software
UPLD
|
+$18.8M |
| 2 |
GLIBA
GCI Liberty, Inc. Class A Common Stock (DE)
GLIBA
|
+$15.7M |
| 3 |
Waste Management
WM
|
+$12.3M |
| 4 |
Amazon
AMZN
|
+$10.3M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
+$10M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$17.6M |
| 2 |
Mastercard
MA
|
+$17M |
| 3 |
Elevance Health
ELV
|
+$13.4M |
| 4 |
AABA
Altaba Inc
AABA
|
+$11.1M |
| 5 |
Netflix
NFLX
|
+$8.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.68% |
| 2 | Communication Services | 35.62% |
| 3 | Healthcare | 8.12% |
| 4 | Consumer Discretionary | 7.37% |
| 5 | Financials | 7.07% |
Similar funds
SCA
KWM
NF
PCG
BA
EL
CFN
BRWM
Tiger Eye Capital's Q2 2019 Portfolio in Review
As of Q2 2019, Tiger Eye Capital held 52 positions worth $480M, up 17% from $412M the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Tiger Eye Capital deployed $33.5M of net new capital in Q2 2019, opening 8 new positions and adding to 12 existing holdings. Its largest new stake was Upland Software: 41,068 shares worth $18.7M.
By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 31% a quarter earlier, followed by Communication Services and Healthcare.
On the sell side, the largest reduction was Thermo Fisher Scientific, an estimated $17.6M trimmed.
- Tiger Eye Capital's largest Q2 2019 buy was Upland Software: 41,068 shares worth $18.7M.
- Tiger Eye Capital added most to GCI Liberty, Inc. Class A Common Stock (DE) in Q2 2019, an estimated $15.7M increase.
- Tiger Eye Capital's biggest Q2 2019 reduction was Thermo Fisher Scientific, cutting an estimated $17.6M.
- Tiger Eye Capital fully exited Mastercard in Q2 2019, selling an estimated $17M.
- Tiger Eye Capital's ten largest holdings make up 69% of its $480M portfolio in Q2 2019.
- Tiger Eye Capital opened 8 new positions and closed 6 in Q2 2019.
- Tiger Eye Capital's portfolio value rose 17% quarter-over-quarter to $480M.
Based on Tiger Eye Capital's 13F filing for Q2 2019, filed 14 Aug 2019.